Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Nature recently talked with CSL’s Roberta Duncan and other experts in the field to explain the innovation of self-amplifying …
The medical specialty gets its name from “nephros,” the Greek word for kidney.
CSL joined the Global Chain of Lights to light up the night on February 29 to acknowledge the millions who live with rare dis…
EURORDIS, which represents rare disease patients in Europe, celebrates advocates who distinguish themselves in categories inc…
Since 1910, the national organization has been creating opportunities for underserved communities. This month, the President …
A new survey of more than 1,000 U.S. residents finds that few know how common rare diseases are, but 85% said it was importan…
Few Australians understand how common rare diseases are, but 89% said it was important to research innovative new treatments,…
This February 29, we bring our collective focus to the cause and demonstrate the power of showing our stripes, says therapist…
CSL has extended its partnership with BaseLaunch, a Basel-area biotech accelerator and incubator for therapeutic ventures.
Americas
Asia Pacific
Middle East
Europe
